About Ribosomal protein S6 kinase-related protein
Ribosomal protein S6 kinase-related protein (RSKR) is a protein
from Homo sapiens identified by UniProt accession
Q96LW2, 410 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | Ribosomal protein S6 kinase-related protein |
| UniProt accession | Q96LW2 |
| Gene | RSKR |
| Organism | Homo sapiens |
| Length | 410 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (11)
Diseases linked to this target (Open Targets).
- insomnia measurement · score 0.06
- ependymoma · score 0.01
- astrocytoma · score 0.01
- diabetes mellitus · score 0.01
- clear cell renal carcinoma · score 0.01
- tuberculosis · score 0.00
- invasive breast ductal carcinoma · score 0.00
- progressive supranuclear palsy · score 0.00
- lung adenocarcinoma · score 0.00
- type 2 diabetes mellitus · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96LW2-F1 | alphafold | PREDICTED | 75.79 | — |
Amino-acid sequence (410 residues)
MGAVSCRQGQ HTQQGEHTRV AVPHKQGGNI RGPWARGWKS LWTGLGTIRS DLEELWELRG HHYLHQESLK PAPVLVEKPL PEWPVPQFIN LFLPEFPIRP IRGQQQLKIL GLVAKGSFGT VLKVLDCTQK AVFAVKVVPK VKVLQRDTVR QCKEEVSIQR QINHPFVHSL GDSWQGKRHL FIMCSYCSTD LYSLWSAVGC FPEASIRLFA AELVLVLCYL HDLGIMHRDV KMENILLDER GHLKLTDFGL SRHVPQGAQA YTICGTLQYM APEVLSGGPY NHAADWWSLG VLLFSLATGK FPVAAERDHV AMLASVTHSD SEIPASLNQG LSLLLHELLC QNPLHRLRYL HHFQVHPFFR GVAFDPELLQ KQPVNFVTET QATQPSSAET MPFDDFDCDL ESFLLYPIPA
Explore Ribosomal protein S6 kinase-related protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets